RAD 2025: Safety and tolerability of roflumilast cream 0.15% was demonstrated in a pooled subgroup analysis of phase 3 study participants unresponsive to or intolerant of previous topical therapy.

RAD 2025: This unique study design simulates the real-world use of JAK inhibitors in tailored treatment regimens with flexibility to manage AEs.

RAD 2025: More than 80% of people would want, or would consider, a test that would direct them towards a more effective therapy for their AD, according to new data.

RAD 2025: Arcutis Biotherapeutics will present promising long-term data on roflumilast cream, focused on effectiveness and safety for treating atopic dermatitis in young children.

Hear experts' takeaways from ACOG 2025 on menopause care, postpartum depression screening, and obesity management.

A study reveals low clinician engagement in digital cognitive assessments for dementia in primary care, highlighting workflow and other barriers to early detection.

Discover the latest breakthroughs in clinical research, from at-home cancer screening to AI advancements in mammography, shaping future healthcare practices.

Social determinants including partner status, smoking history, and BMI were significantly associated with reduced access to effective hormone therapy for menopausal women.

Breakthrough device designation for the multicancer detection test is supported by clinical validation data demonstrating an overall specificity of 98.6% and sensitivity of 60%.

Your daily dose of the clinical news you may have missed.